UPSHER-SMITH LAUNCHES NEW EPILEPSY-FOCUSED WEBSITE AT AES ANNUAL MEETING
Epilog.us Provides Epilepsy-Focused Educational Resource For Healthcare Professionals
Maple Grove, MN — December 2, 2011 /PRNewswire/ — Upsher-Smith Laboratories, Inc. [http://www.upsher-smith.com] today announced plans to launch its new epilepsy-focused educational website, www.Epilog.us, at the American Epilepsy Society (AES) annual meeting, December 3-5, 2011. The new website will be featured at the Upsher-Smith booth (# 102) and marks an important landmark in the Company’s commitment to the epilepsy community.
Epilog.us is an epilepsy-focused, disease awareness website offering healthcare professionals who treat epilepsy current evidence-based scientific data, modern therapy issues and expert insights provided by some of the field’s most respected clinicians.
“Epilog.us provides healthcare professionals with targeted clinical information that may help inform their treatment decisions,” said Tom Burke, Executive Vice President, Upsher-Smith. “Epilog.us complements our overarching vision to become a leader in providing novel solutions for people with epilepsy. We are proud to debut Epilog.us with the attendees at this year’s AES annual meeting.”
The site will feature regularly updated white papers, podcasts and interactive components addressing various epilepsy-related topics. At launch, Epilog.us will feature information and data specifically related to Women and Epilepsy. Future topics might include Epilepsy and Comorbidities, Monotherapy vs. Polytherapy, Brands and Generics in the treatment of epilepsy, and Drug Delivery Advances.
Upsher-Smith’s Expanding CNS Pipeline
Upsher-Smith’s central nervous system (CNS) pipeline includes a number of investigational drug programs for various indications within epilepsy, including USL255, USL261, and USL260.
Epilepsy is a medical condition that produces seizures affecting a variety of mental and physical functions. Almost three million people in the U.S. have some form of epilepsy with about 200,000 new cases of epilepsy diagnosed each year.¹
Upsher-Smith Laboratories, Inc., founded in 1919, is a rapidly growing, privately held pharmaceutical company that develops, manufactures, and markets prescription and consumer products. Upsher-Smith’s product portfolio focuses in the areas of women’s health, dermatology, cardiology, and CNS diseases. The company’s focus is growing a CNS pipeline for diseases with significant unmet need, including epilepsy and Parkinson’s disease. To expand its CNS pipeline, Upsher-Smith seeks alliances and co-development programs, pursues licensing and acquisitions, and leverages its core competency in formulation development. For more information, visit http://www.upsher-smith.com.
1. Epilepsy Foundation. Available at: http://www.epilepsyfoundation.org/. Accessed on March 18, 2011.